Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Completed 5Unknown 2Terminated 2Withdrawn 1No longer available 1Active not recruiting 1

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced or Metastatic Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × efineptakin alfa × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

NeoImmuneTech

Phase 1 Completed
17 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03752723 2024-03-05

KEYNOTE-899

Genexine, Inc.

Phase 1/2 Completed
84 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03733587 2020-05-14

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Genexine, Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumor

NCT03478995 2020-05-11

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Genexine, Inc.

Phase 1 Completed
35 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡